1. Towards Understanding Tumour Colonisation by Probiotic Bacterium E. coli Nissle 1917.
- Author
-
Radford, Georgette A., Vrbanac, Laura, de Nys, Rebekah T., Worthley, Daniel L., Wright, Josephine A., Hasty, Jeff, and Woods, Susan L.
- Subjects
- *
GENETIC engineering , *EARLY detection of cancer , *IMMUNOTHERAPY , *HOST-bacteria relationships , *CANCER patients , *DRUG delivery systems , *HAZARDOUS substance safety measures , *ESCHERICHIA coli , *BACTERIA , *PROBIOTICS , *TUMORS , *BACTERIAL diseases , *BIOSECURITY - Abstract
Simple Summary: Tumour-homing bacteria present as an ideal chassis for cancer treatment and detection. A decade of pre-clinical and clinical research with the tumour-homing bacteria Escherichia coli Nissle 1917 (EcN) has demonstrated that genetic modification for payload delivery can lead to significant tumour regression and, more recently, tumour detection. Currently unknown in the field is a deep mechanistic understanding of why bacteria home to and colonise tumours. This review summarises existing literature to provide insight into the tumour-homing and colonising ability of EcN, in addition to exploring other tumour-homing strains and pathogenic bacteria for a more in-depth view. A mechanistic understanding of this capability could prove invaluable in the development of the next-generation EcN chassis for tumour detection and treatment, as well as address biosafety and containment concerns necessary for clinical translation. The last decade has seen a rapid increase in studies utilising a genetically modified probiotic, Escherichia coli Nissle 1917 (EcN), as a chassis for cancer treatment and detection. This approach relies on the ability of EcN to home to and selectively colonise tumours over normal tissue, a characteristic common to some bacteria that is thought to result from the low-oxygen, nutrient-rich and immune-privileged niche the tumour provides. Pre-clinical studies have used genetically modified EcN to deliver therapeutic payloads that show efficacy in reducing tumour burden as a result of high-tumour and low off-target colonisation. Most recently, the EcN chassis has been expanded into an effective tumour-detection tool. These advances provide strong justification for the movement of genetically modified EcN into clinical oncology trials. What is currently unknown in the field is a deep mechanistic understanding of how EcN distributes to and localises within tumours. This review summarises the existing EcN literature, with the inclusion of research undertaken with other tumour-homing and pathogenic bacteria, to provide insights into possible mechanisms of EcN tumour homing for future validation. Understanding exactly how and why EcN colonises neoplastic tissue will inform the design and testing of the next generation of EcN chassis strains to address biosafety and containment concerns and optimise the detection and treatment of cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF